InflaRx (IFRX) Competitors $2.24 +0.11 (+5.16%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IFRX vs. ANAB, CRMD, MREO, XERS, ABVX, MGTX, RNAC, GLUE, TKNO, and ORGOShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include AnaptysBio (ANAB), CorMedix (CRMD), Mereo BioPharma Group (MREO), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Cartesian Therapeutics (RNAC), Monte Rosa Therapeutics (GLUE), Alpha Teknova (TKNO), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. AnaptysBio CorMedix Mereo BioPharma Group Xeris Biopharma ABIVAX Société Anonyme MeiraGTx Cartesian Therapeutics Monte Rosa Therapeutics Alpha Teknova Organogenesis InflaRx (NASDAQ:IFRX) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking. Does the media favor IFRX or ANAB? In the previous week, AnaptysBio had 21 more articles in the media than InflaRx. MarketBeat recorded 26 mentions for AnaptysBio and 5 mentions for InflaRx. InflaRx's average media sentiment score of 0.58 beat AnaptysBio's score of 0.20 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate IFRX or ANAB? InflaRx presently has a consensus price target of $8.00, suggesting a potential upside of 257.14%. AnaptysBio has a consensus price target of $41.45, suggesting a potential upside of 184.91%. Given InflaRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe InflaRx is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders believe in IFRX or ANAB? 42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 33.7% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor IFRX or ANAB? AnaptysBio received 129 more outperform votes than InflaRx when rated by MarketBeat users. Likewise, 66.01% of users gave AnaptysBio an outperform vote while only 64.67% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformInflaRxOutperform Votes23864.67% Underperform Votes13035.33% AnaptysBioOutperform Votes36766.01% Underperform Votes18933.99% Which has stronger valuation and earnings, IFRX or ANAB? InflaRx has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$168.50K782.79-$46.18M-$1.08-2.07AnaptysBio$57.17M7.74-$163.62M-$6.08-2.39 Which has more volatility & risk, IFRX or ANAB? InflaRx has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Is IFRX or ANAB more profitable? AnaptysBio has a net margin of -289.75% compared to InflaRx's net margin of -33,362.70%. InflaRx's return on equity of -65.98% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets InflaRx-33,362.70% -65.98% -56.86% AnaptysBio -289.75%-287.94%-37.25% SummaryInflaRx beats AnaptysBio on 10 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.42M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-2.0710.5489.7417.18Price / Sales782.79195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book1.195.094.774.78Net Income-$46.18M$151.83M$120.15M$225.60M7 Day Performance-5.08%-2.13%-1.92%-1.23%1 Month Performance8.74%-3.10%11.47%3.36%1 Year Performance51.35%11.54%30.52%16.60% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.4025 of 5 stars$2.24+5.2%$8.00+257.1%+50.3%$125.42M$168,498.00-2.0760Analyst ForecastNews CoveragePositive NewsANABAnaptysBio2.3125 of 5 stars$17.01+9.1%$45.09+165.1%-25.4%$517.61M$17.16M-2.80100Analyst ForecastCRMDCorMedix1.8468 of 5 stars$8.39+0.1%$15.20+81.2%+147.0%$509.08M$12.26M-10.3530Analyst ForecastNews CoveragePositive NewsMREOMereo BioPharma Group2.0953 of 5 stars$3.27-12.6%$7.40+126.3%+68.3%$507.33M$1M0.0040High Trading VolumeXERSXeris Biopharma3.6033 of 5 stars$3.40+3.7%$4.87+43.1%+73.6%$506.87M$163.91M-7.29290News CoveragePositive NewsABVXABIVAX Société Anonyme2.1863 of 5 stars$7.98+12.2%$38.67+384.5%-27.6%$505.52MN/A0.0061Positive NewsGap DownMGTXMeiraGTx3.8637 of 5 stars$6.41+4.7%$23.50+266.6%+25.3%$500.96M$13.93M-5.06300News CoverageRNACCartesian Therapeutics2.2994 of 5 stars$19.06+2.0%$43.00+125.6%-6.3%$484.51M$26M-0.3537Analyst ForecastNews CoverageGLUEMonte Rosa Therapeutics1.9132 of 5 stars$7.78+2.9%$16.00+105.7%+28.3%$477.98M$14.98M-4.1390Analyst DowngradeNews CoverageTKNOAlpha Teknova0.4761 of 5 stars$8.81+9.7%$5.00-43.2%+124.1%$469.66M$36.68M-11.73240Gap UpORGOOrganogenesis4.222 of 5 stars$3.52+3.5%$5.33+51.5%-20.6%$466.68M$433.14M-56.67950 Related Companies and Tools Related Companies AnaptysBio Competitors CorMedix Competitors Mereo BioPharma Group Competitors Xeris Biopharma Competitors ABIVAX Société Anonyme Competitors MeiraGTx Competitors Cartesian Therapeutics Competitors Monte Rosa Therapeutics Competitors Alpha Teknova Competitors Organogenesis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IFRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
